ALSO NOTED: ISTA announces positive data; Proteolix launches Phase II trial; and much more...

> If anyone doubted Andrew Witty's professed faith in emerging markets, those doubts can be put to rest. The incoming GlaxoSmithKline CEO lured Eli Lilly's Abbas Hussein to spearhead a new unit charged with building business in China, Russia, Brazil, India and the Middle East. GSK report

> ISTA Pharmaceuticals announced positive preliminary results from its second and final late-stage study of Bepreve. ISTA release

> Proteolix has launched a Phase II clinical trial of carfilzomib (PR-171), a selective blocker of proteasome activity, in relapsed solid tumors. Proteolix release

> Oncothyreon has filed an investigational new drug for PX-866, a small molecule phosphatidylinositol-3-kinase inhibitor for advanced cancers. Oncothyreon release

> The FDA has given Merck 15 days to decide how to fix manufacturing problems at its main vaccine plant in West Point, PA, according to a warning letter dated April 30. Report

> As the U.K. nears a long-term drug-pricing deal with pharma firms, drugmakers are grousing about the fact that the government decided to renegotiate at all. Report

> Pfizer is breathing a big sigh of relief. The U.S. Patent & Trademark Office has said it will confirm the drugmaker's basic patent on the blockbuster Lipitor drug. Report

Special Report... CEO Pay: Who makes what in Big Biotech? Report

And Finally... A large group of American parents are having a tough time keeping up with their kids' vaccination schedules. Vaccine report

Suggested Articles

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.

In our EuroBiotech roundup this week, a liver disease biotech raises €11 million, Autolus offers stock and Abivax plans midphase trial. 

Merck KGaA spinout iOnctura has raised a €15 million series A round to support an early-phase solid tumor trial of a PI3Kδ inhibitor.